Markets Today: the Asian close, 17 September 2026
The Asian trading day in one place: 5 stories across currencies, central banks, equities and deals, collected at the close.
The close
Indian Equities Face Cautious Open Amid Global Pressures: India's Gift Nifty showed a negative start today as rising US bond yields and elevated crude prices weighed on sentiment, following Tuesday's broad declines.
Central banks & currencies
RBI Absorbs ₹6.7 Trillion in Liquidity as Overnight Rates Stabilise: India's central bank pulled significant funds from the banking system on 15 September, while overnight money market volumes reached over ₹7 trillion at a 4.80% weighted average rate.
IPO & deals
GSK secures global rights to Chimagen cancer drug in US$750 million deal: British pharmaceutical firm GSK announced on Tuesday its acquisition of global rights to a T-cell engager from Chengdu-based Chimagen Biosciences for treating multiple myeloma.
Prasol Chemicals IPO Opens, Grey Market Premium Points to 8% Gain: Prasol Chemicals' ₹500 crore initial public offering (IPO) began bidding today. The speciality chemicals firm aims to raise capital. Grey market premiums (GMP) point to a potential 8% listing gain. Initial subscription levels remain modest.
Brookfield completes A$4.1bn acquisition of Reliance Worldwide: The global plumbing and heating systems manufacturer, listed on the ASX, operates across Asia-Pacific, EMEA, and the Americas.
Every item above was reported and checked separately today; this wrap collects them in one place at the Asian close. Follow any headline through to the full story for the figures and their sources. The Brief carries the same day in five minutes tomorrow morning.
This article is journalism, not investment advice; consult a licensed professional before making financial decisions. Market data is indicative, may be delayed, and should be verified with your broker or exchange before use.
Comments.
Comments are moderated. We remove what is unlawful, abusive or off-topic, and and you remain responsible for what you post.
Reader comments open soon. Until then, corrections and responses go to our newsroom, and we publish what we get wrong on Corrections.